Clinical Trial: Neoadjuvant Imatinib in Dermatofibrosarcoma Protuberans
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: Study of a Short Course of Neoadjuvant Gleevec (Imatinib Mesylate) in Dermatofibrosarcoma Protuberans
Brief Summary: The purpose of this study is to examine the effect of imatinib on dermatofibrosarcoma protuberan tumors.
Detailed Summary:
Sponsor: Sarcoma Alliance for Research through Collaboration
Current Primary Outcome: To Collect Matched Tumor Tissue of Trial Participants With Dermatofibrosarcoma Protuberans Before and After Treatment With Imatinib for Future Use in cDNA Microarray and Tissue Array Studies. [ Time Frame: Prior to and after 2-weeks of imatinib therapy ]
Original Primary Outcome: Comparison of PDGFRB in tumor sample obtained prior to imatinib with sample obtained following 2 weeks of imatinib therapy
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Sarcoma Alliance for Research through Collaboration
Dates:
Date Received: October 20, 2005
Date Started: May 2006
Date Completion:
Last Updated: February 14, 2012
Last Verified: February 2012